M&A Deal Summary |
|
---|---|
Date | 2019-05-16 |
Target | Realm Therapeutics |
Sector | Life Science |
Buyer(s) | ESSA |
Deal Type | Add-on Acquisition |
Deal Value | 22M USD |
Advisor(s) | MTS Health Partners LP (Financial) Cooley Fasken Martineau DuMoulin (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2009 |
Sector | Life Science |
Employees | 25 |
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA was founded in 2009 and is based in Vancouver, Canada.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Pennsylvania) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 1 |